Subject(s)
Cell Transformation, Neoplastic/pathology , Dermatitis, Atopic/pathology , Mycosis Fungoides/pathology , Skin Neoplasms/pathology , Adult , Biopsy, Needle , Dermatitis, Atopic/complications , Dermatitis, Atopic/drug therapy , Facial Dermatoses/drug therapy , Facial Dermatoses/pathology , Female , Humans , Immunohistochemistry , Immunosuppressive Agents/therapeutic use , Mycosis Fungoides/complications , Mycosis Fungoides/drug therapy , Prognosis , Risk Assessment , Scalp Dermatoses/drug therapy , Scalp Dermatoses/pathology , Skin Neoplasms/complications , Skin Neoplasms/drug therapyABSTRACT
RATIONALE: Ecthyma gangrenosum (EG) is an aggressive cutaneous disease caused by local or systemic infection with Pseudomonas aeruginosa. EG is characterized by cutaneous manifestations ranging from nodule and papule, to necrotic ulceration with surrounding erythema, especially with black eschar or central crust. EG presents with characteristic skin lesions which is important to establish diagnosis of sepsis caused by P aeruginosa, a serious condition that can be treated efficiently if diagnosed early. PATIENT CONCERNS: A 3-month-old female infant was presented with characteristic skin lesions of EG and developed sepsis 3 days later. DIAGNOSES: Ecthyma gangrenosum and sepsis caused by Pseudomonas aeruginosa. INTERVENTIONS: Meropenem was used in combination with ceftazidime at first and excision of necrotic skin lesions was performed later. OUTCOMES: Cure. LESSONS: Early recognition of EG plays an important role in providing appropriate empiric antibiotic treatment at early stage of sepsis, and improves the prognosis. Surgical excision may be helpful if no improvement was achieved via antibiotic treatment.
Subject(s)
Gangrene/microbiology , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/isolation & purification , Pyoderma Gangrenosum/microbiology , Sepsis/microbiology , Anti-Bacterial Agents/therapeutic use , Ceftazidime/therapeutic use , Female , Gangrene/drug therapy , Gangrene/surgery , Humans , Infant , Meropenem , Pseudomonas Infections/surgery , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/surgery , Sepsis/drug therapy , Sepsis/surgery , Thienamycins/therapeutic useSubject(s)
Dyskeratosis Congenita/pathology , Cell Cycle Proteins/genetics , Dermoscopy , Dyskeratosis Congenita/complications , Dyskeratosis Congenita/genetics , Humans , Hyperpigmentation/etiology , Leukoplakia, Oral/etiology , Male , Nail Diseases/etiology , Nuclear Proteins/genetics , Young AdultABSTRACT
OBJECTIVE: To establish a modified plasma protamine paracoagulation test. METHODS: Plasma protamine paracoagulation, modified plasma protamine paracoagulation and D-dimer (D-D) tests were performed for the plasma samples collected from 98 cases of disseminated intravascular coagulation (DIC) and 156 normal subjects. The sensitivity and specificity of the 3 tests were analyzed. The plasma samples from 8 cases of suspected myocardial infarction were detected using modified plasma protamine paracoagulation for diagnostic purpose. RESULTS: The sensitivity of plasma protamine paracoagulation, modified plasma protamine paracoagulation and D-D tests was 16.33%, 88.76% and 77.56%, and the specificity was 100%, 88.46% and 97.44%, respectively. Positive results occurred earlier in modified plasma protamine paracoagulation test than in plasma protamine paracoagulation and D-D tests in 5 cases of myocardial infarction. CONCLUSION: The modified plasma protamine paracoagulation test has a higher sensitivity than plasma protamine paracoagulation test and a higher specificity than D-D test, and can be helpful in early diagnosis of thrombosis and fibrinolysis.
